Figure 3.

Potential functional relevance between CBX2 and EZH2

(A) Kaplan-Meier survival curve for patients with high (>median expression) or low (<median expression) expression of CBX2 or EZH2. The survival difference was determined by log rank test. According to a standard procedure, tumor samples were grouped into high and low groups by the median expression of specific gene. The median survival times were marked by a dashed line. (B) Kaplan-Meier survival curve of the combined CBX2 and EZH2 expression. (C) The proteins expression of CBX2 and EZH2 detected by immunohistochemistry of LUAD microarrays (scale bar, 50 μm) and (D) their quantification in human LUAD (n = 75) and adjacent normal tissues (n = 75). ∗∗∗p ≤ 0.001. (E) The Spearman correlation between CBX2 and EZH2 protein expression levels in LUAD tissue microarrays (n = 75). (F) Spearman correlation between CBX2 and EZH2 mRNA expression levels in TCGA tumor samples. In (E) and (F), r: correlation coefficient; n: number of samples.